Parasitic infections are caused by a diverse group of organisms, including protozoa, helminths (worms), and ectoparasites, and they represent a significant global health burden. These infections can affect various organs and systems, leading to a wide range of diseases with varying severity. Protozoan parasites, such as Plasmodium causing malaria and Trypanosoma causing sleeping sickness, can result in life-threatening illnesses. Helminthic infections, including schistosomiasis and intestinal worm infestations, contribute to chronic morbidity, malnutrition, and impaired growth. Transmission of parasitic infections often occurs through contaminated food, water, or vectors like mosquitoes and ticks. Poor sanitation, poverty, and limited access to healthcare contribute to the prevalence of parasitic diseases in many regions. Control and prevention strategies involve medications, vector control, and public health measures. Developing effective vaccines against parasitic infections remains a challenge but is an active area of research. Understanding the complex life cycles and host-parasite interactions is crucial for devising comprehensive strategies to combat parasitic infections and improve global health outcomes.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom